Deprescribing anticholinergics to preserve brain health: reducing the risk of dementia through deprescribing (R2D2): study protocol for a randomized clinical trial.

Autor: Campbell NL; Department of Pharmacy Practice, Purdue University College of Pharmacy, West Lafayette, IN, USA. campbenl@purdue.edu.; Indiana University Center for Aging Research, Regenstrief Institute, Inc, Indianapolis, IN, USA. campbenl@purdue.edu.; Center for Health Innovation and Implementation Science, Indiana University, Indianapolis, IN, USA. campbenl@purdue.edu., Holden RJ; Center for Health Innovation and Implementation Science, Indiana University, Indianapolis, IN, USA.; Department of Health & Wellness Design, Indiana University School of Public Health, Bloomington, IN, USA., Gao S; Department of Biostatistics and Health Data Science, Indiana University School of Medicine, Indianapolis, IN, USA., Unverzagt FW; Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, USA., Lane KA; Department of Biostatistics and Health Data Science, Indiana University School of Medicine, Indianapolis, IN, USA., Carter A; Department of Biostatistics and Health Data Science, Indiana University School of Medicine, Indianapolis, IN, USA., Harrington AB; Indiana University Center for Aging Research, Regenstrief Institute, Inc, Indianapolis, IN, USA., Manoharan S; Indiana University Center for Aging Research, Regenstrief Institute, Inc, Indianapolis, IN, USA., Manoharan N; Indiana University Center for Aging Research, Regenstrief Institute, Inc, Indianapolis, IN, USA., Rosenthal DL; Indiana University Center for Aging Research, Regenstrief Institute, Inc, Indianapolis, IN, USA., Pitts C; Department of Pharmacy, Indiana University Health, Indianapolis, IN, USA., Pelkey K; Department of Pharmacy, Community Health Network, Indianapolis, IN, USA., Papineau E; Department of Pharmacy, Community Health Network, Indianapolis, IN, USA., Lauck DM; Department of Medicine, Community Health Network, Indianapolis, IN, USA., Keshk N; Department of Pharmacy Practice, Purdue University College of Pharmacy, West Lafayette, IN, USA., Alamer K; Pharmacy Practice Department, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia., Khalil H; Department of Pharmacy Practice, Purdue University College of Pharmacy, West Lafayette, IN, USA., Boustani MA; Indiana University Center for Aging Research, Regenstrief Institute, Inc, Indianapolis, IN, USA.; Center for Health Innovation and Implementation Science, Indiana University, Indianapolis, IN, USA.; Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.
Jazyk: angličtina
Zdroj: Trials [Trials] 2024 Nov 22; Vol. 25 (1), pp. 788. Date of Electronic Publication: 2024 Nov 22.
DOI: 10.1186/s13063-024-08618-4
Abstrakt: Background: Older adults commonly experience chronic medical conditions and are at risk of cognitive impairment as a result of age, chronic comorbidity, and medications prescribed to manage multiple chronic conditions. Anticholinergic medications are common treatments for chronic conditions and have been repeatedly associated with poor cognitive outcomes, including delirium and dementia, in epidemiologic studies. However, no study has definitively evaluated the causal relationship between anticholinergics and cognition in a randomized controlled trial design. Utilizing our prior experience in deprescribing anticholinergic medications in various clinical environments, we designed an outpatient deprescribing intervention to prospectively test the potential causal relationship between anticholinergics and cognition in primary care older adults.
Methods: This cluster randomized clinical trial will be conducted to evaluate the impact of an anticholinergic deprescribing intervention compared to usual care on outcomes of cognition and safety in primary care older adults. Participants will include those aged 65 years and over, receiving primary care in the greater Indianapolis area, using a strong anticholinergic within the last 2 weeks or with evidence of high-risk exposure in the past year. Those excluded will have a diagnosis of Alzheimer's disease or related dementia, or serious mental illness. The trial plans to enroll 344 participants who will be cluster-randomized at the level of primary care physician to avoid contamination. Participants will complete outcome assessments every 6 months up to 2 years by blinded outcome assessors. The primary outcome of the study is a composite measure of cognition that includes domains assessing executive cognitive function, language, and memory. Secondary outcomes include patient-reported measures of pain intensity, depression, anxiety, sleep disturbance, and health-related quality of life.
Discussion: The R2D2 trial will be the largest and longest prospective randomized trial testing the impact of an anticholinergic-specific deprescribing intervention on cognition in primary care older adults. Results could influence deprescribing methodology and provide new insight on the relationship between anticholinergics and cognition.
Trial Registration: ClinicalTrials.gov NCT04270474. Registered on February 17, 2020.
Competing Interests: Declarations. Ethics approval and consent to participate: All procedures have received and maintained ethical approval from the Institutional Review Board of the Indiana University (IRB# 1811254189; Federal-Wide Assurance Number, FWA00003544). The trial has also been registered at ClinicalTrials.gov (Identifier: NCT04270474). Consent for publication: Not applicable—no identifying images or other personal or clinical details of individual participants are presented here or will be presented in reports of the trial results. The participant information materials and informed consent form are available from the corresponding author on request. Competing interests: Dr. Boustani serves as a Chief Scientific Officer and co-Founder of Blue Agilis; the Chief Health Officer of DigiCare Realized, Inc; and the Chief Health Officer of Mozyne Health, Inc. He has equity interest in Blue Agilis, Inc; DigiCare Realized, Inc; and Mozyne Health, Inc. He sold his equity in Preferred Population Health Management LLC and MyShift, Inc (previously known as RestUp, LLC). He serves as an advisory board member or consultant for Eli Lilly and Co; Eisai, Inc; Merck & Co Inc; Biogen Inc; and Genentech Inc. These conflicts have been reviewed by Indiana University and has been appropriately managed to maintain objectivity. All other authors report no conflicts of interest.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje